Oncolytics Biotech Inc.
NASDAQ:ONCYBiotechnology
+$0.03 today
- Market cap
- $50.41M
- Beta
- 1.08
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$0.32
Volume 0.38M
Average 1.26M
ONCY Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Oncolytics Biotech Inc.NASDAQ: ONCY
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses growth accelerates
Q1 FY2026 operating expenses of CA$12.92M rose 84.6% year over year, ahead of the +14.2% change in trailing-twelve-month operating expenses. Sequentially, it rose 332.0% from the prior quarter. Over 3 fiscal years it compounded at +24.6% a year.
Context
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +84.6% holds above the trailing-twelve-month pace of +14.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
CAD · from the income statement
- Latest · FY2025
- 39.41M CAD
- Year-over-year change
- +12.7%
- 4-year CAGR
- +17.7%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 39.41M | +12.7% |
| FY2024 | 2024-12-31 | 34.98M | +41.4% |
| FY2023 | 2023-12-31 | 24.74M | +21.4% |
| FY2022 | 2022-12-31 | 20.38M | -0.9% |
| FY2021 | 2021-12-31 | 20.56M | — |
Operating Expenses vs competitors
How ONCY compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +14.2% is the 5th highest of 9, against a peer median of +12.5%.
- Over three fiscal years its annual growth of +24.6% compares with a peer median of -8.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $173.51M USD | -10.6% | -12.1% | 110.5% | |
| LTM Mar 2026 | $144.89M USD | -39.4% | -12.4% | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $122.7M USD | +143.6% | +40.1% | — |
| LTM Mar 2026 | $54.01M USD | -31.7% | -36.0% | — | |
| LTM Mar 2026 | $50.43M USD | +35.5% | -5.6% | 672.9% | |
| LTM Mar 2026 | $35.95M USD | +65.2% | +48.4% | — | |
| LTM Mar 2026 | CA$35.46M CAD | +14.2% | +24.6% | — | |
| LTM Mar 2026 | $29.92M USD | +225.6% | +73.5% | 376.8% | |
| LTM Mar 2026 | $20.57M USD | -27.1% | -21.9% | 15353.0% | |
| Peer median (excluding ONCY) | — | +12.5% | -8.9% | 524.8% | |
Competitors are the stored peer set for ONCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 360.58K | 301.11K | 298.59K | 87K | 70K |
| Gross Profit | (360.58K) | (301.11K) | (298.59K) | (87K) | (70K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 10.31M | 11.85M | 13.12M | 21.65M | 18.27M |
| Selling, General & Admin | 10.26M | 8.53M | 11.62M | 13.34M | 21.15M |
| Operating Expenses | 20.56M | 20.38M | 24.74M | 34.98M | 39.41M |
| Depreciation & Amortization | 360.58K | 301.11K | 298.59K | 102K | 96.05K |
| EBITDA | (20.58M) | (18.71M) | (20.19M) | (34.88M) | (39.41M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (20.93M) | (20.68M) | (25.04M) | (34.98M) | (39.41M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 99K | 528K | 1.33M | 1.2M | 529.64K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (15.88K) | 1.67M | 4.55M | 3.4M | 61.75K |
| Income Before Tax | (20.94M) | (19.01M) | (20.49M) | (31.58M) | (39.35M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 39.42K | 64.52K | 71.87K | 130K | 108.4K |
| Net Income | (20.98M) | (19.08M) | (20.56M) | (31.71M) | (39.46M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.49) | (0.44) | (0.41) | (0.41) | (0.41) |
| EPS (Diluted) | (0.49) | (0.44) | (0.41) | (0.41) | (0.41) |
| Weighted Avg Shares | 53.51M | 58.03M | 67.62M | 76.48M | 95.86M |
| Weighted Avg Shares (Diluted) | 53.51M | 58.03M | 67.62M | 76.48M | 95.86M |
Oncolytics Biotech Inc.
NASDAQ:ONCY
Intrinsic Alpha fair value
Locked
Current Price
$0.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.